Pinnacle Wealth Planning Services Inc. Sells 415 Shares of Stryker Co. (NYSE:SYK)

Pinnacle Wealth Planning Services Inc. reduced its stake in Stryker Co. (NYSE:SYK) by 21.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,542 shares of the medical technology company’s stock after selling 415 shares during the quarter. Pinnacle Wealth Planning Services Inc.’s holdings in Stryker were worth $555,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC bought a new position in Stryker in the 4th quarter worth $25,000. Dunhill Financial LLC raised its holdings in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the period. Centricity Wealth Management LLC bought a new position in Stryker in the 4th quarter worth $30,000. BankPlus Trust Department bought a new position in Stryker in the 4th quarter worth $33,000. Finally, Darwin Wealth Management LLC bought a new position in Stryker in the 3rd quarter worth $36,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 3.5 %

SYK opened at $381.86 on Friday. The firm has a market cap of $145.71 billion, a P/E ratio of 49.21, a P/E/G ratio of 2.93 and a beta of 0.96. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average of $382.21 and a 200 day moving average of $372.52.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company earned $3.46 earnings per share. As a group, research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on SYK. Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Canaccord Genuity Group increased their price target on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. The Goldman Sachs Group increased their price target on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday, January 30th. Finally, Wells Fargo & Company increased their price target on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.